Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer

Official Title

Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer

Summary:

This trial is being conducted to determine the impact of whole body FDG PET-CT vs. conventional staging in the management of patients presenting with clinical Stage III breast cancer. Eligible consenting patients with ductal or mixed histology breast cancer will be randomized 1:1 to whole body FDG PET-CT or conventional staging. Eligible consenting patients with lobular only histology will be entered into a separate single arm prospective study and will undergo whole body FDG PET-CT, CT with contrast of the chest/abdomen & pelvis and a bone scan.

Trial Description

Primary Outcome:

  • Proportion of patients upstaged to Stage IV disease
Secondary Outcome:
  • Proportion of patients who receive multimodal therapy of curative intent
  • Number of additional tests, such as imaging and biopsy, resulting from findings of study imaging
  • Prognostic ability of PET SUV of the primary lesion on the pathological response rate to neo-adjuvant chemotherapy
  • Disease Free Survival
  • Overall Survival
  • Incremental economic analysis comparing the costs and outcomes of the treatment arms

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society